Optimal tolerability of ultra-low-dose continuous combined 17β-estradiol and norethisterone acetate: laboratory and safety results

References

• Birkhaeuser MH, Panay N, Archer DF, et al Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008;11:108–123
   PubMed Web of Science ®Google Scholar
• Pines A, Sturdee DW, Birkhaeuser MH, et al IMS Updated Recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181–194
   PubMed Web of Science ®Google Scholar
• Greenwald MWM, Gluck OSMF, Lang EM, Rakov VM. Oral hormone therapy with 17β-estradiol and 17β-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause 2005;12:741–748
   PubMed Web of Science ®Google Scholar
• Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998;105:904–911
   PubMedGoogle Scholar
• Ettinger B, Ensrud KE, Wallace R, et al Effects of ultralow-dose transdermal estradiol on bone mineral density: A randomized clinical trial. Obstet Gynecol 2004;104:443–451
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Lenihan JP, Jr, McDermott M, Kerber IJ, Nanavati N, Arce JC. Initial 17β-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726–731
   PubMed Web of Science ®Google Scholar
• Barentsen R, Groeneveld FPMJ, Bareman FP, Hoes AW, Dokter HJ, Drogendijk AC. Women's opinion on withdrawal bleeding with hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 1993;51:203–207
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Félix JC, Archer DF, Nanavati N, Arce J, Moyer DL. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol 2000;96:373–379
   PubMed Web of Science ®Google Scholar
• Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10:120–131
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Archer DF, Rakov V, Lang E, Investigators on behalf of the CHOICE Study. Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. Climacteric 2008;11:63–73
   PubMed Web of Science ®Google Scholar
• Lundstrom E, Bygdeson M, Svane G, Azavedo E, von Schoultz B. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. Climacteric 2007;10:249–256
   PubMed Web of Science ®Google Scholar
• Perez GS, Garcia Rodriguez LA, Castellsague J, Duque OA. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997;314:796–800
   PubMed Web of Science ®Google Scholar
• Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981–983
   PubMed Web of Science ®Google Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(Suppl 1):3–63
   PubMed Web of Science ®Google Scholar
• Lang E, Rakov V. Are all HRT preparations the same? In Schneider HPG, Naftolin F, eds. Climacteric Medicine – where do we go. London: Parthenon Publishing, 2004:136–144
   Google Scholar
• Wiegratz I, Kuhl H. Progestogen therapies: differences in clinical effects? Trends Endocrinol Metab 2004;15:277–285
   PubMed Web of Science ®Google Scholar
• Li C, Samsioe G, Borgfeldt C, Bendahl PO, Wilawan K, Aberg A. Low-dose hormone therapy and carbohydrate metabolism. Fertil Steril 2003;79:550–555
   PubMed Web of Science ®Google Scholar
• Kanaya AM, Herrington D, Vittinghoff E, et al Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1–9
   PubMed Web of Science ®Google Scholar
• Margolis KL, Bonds DE, Rodabough RJ, et al Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004;47:1175–1187
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538–554
   PubMed Web of Science ®Google Scholar
• Iranmanesh A, Veldhuis JD. Clinical pathophysiology of the somatotropic (GH) axis in adults. Endocrinol Metab Clin North Am 1992;21:783–816
   PubMed Web of Science ®Google Scholar
• Westley BR, May FE. Role of insulin-like growth factors in steroid modulated proliferation. J Steroid Biochem Mol Biol 1994;51:1–9
   PubMed Web of Science ®Google Scholar
• Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151–156
   PubMed Web of Science ®Google Scholar
• Ma J, Pollak MN, Giovannucci E, et al Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620–625
   PubMed Web of Science ®Google Scholar
• Cullen KJ, Allison A, Martire I, Ellis M, Singer C. Insulin-like growth factor expression in breast cancer epithelium and stroma. Breast Cancer Res Treat 1992;22:21–29
   PubMed Web of Science ®Google Scholar
• Lipworth L, Adami HO, Trichopoulos D, Carlström K, Mantzoros C. Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer. Epidemiology 1996;7:96–100
   PubMed Web of Science ®Google Scholar
• Biglia N, Ambroggio S, Ponzone R, et al Modification of serum IGF-I, IGFBPs and SHBG levels by different HRT regimens. Maturitas 2003;45:283–291
   PubMed Web of Science ®Google Scholar
• Doeren M, Rübig A, Coelingh Bennink HJ, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001;75:554–559
   PubMed Web of Science ®Google Scholar
• Greendale GA, Reboussin BA, Sie A, et al Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999;130:262–269
   PubMed Web of Science ®Google Scholar
• Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, et al The effect of low dose hormone therapy on mammographic breast density. Maturitas 2006;54:78–85
   PubMed Web of Science ®Google Scholar
• Archer DF. Drospirenone and estradiol: a new option for the postmenopausal woman. Climacteric 2007;10(Suppl 1):3–10
   PubMedGoogle Scholar
• Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080–1087
   PubMed Web of Science ®Google Scholar
• Archer DF, Thorneycroft IH, Foegh M, et al Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12:716–727
   PubMed Web of Science ®Google Scholar
• Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065–1079
   PubMed Web of Science ®Google Scholar